ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

04 Jan 2023

─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in rare ocular cancer to be conducted at MD Anderson Cancer Center─

Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA’s PRAME-targeting immunotherapy,

Read more »

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

15 Jul 2022

Recognition of commendable, longstanding dedication to the field of cancer immunotherapy

Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of Immuno-Oncology (FAIO) . The fellowship recognises Prof. Melief’s inspiring contributions and dedication to cancer immunotherapy, and will be presented at the SITC’s 37th Annual Meeting in Boston, 8-12 November 2022.

SITC is a professional society of scientists, clinicians, government representatives, and industry leaders

Read more »